CD4 and non-small cell lung carcinoma: A cohort study with 179 NSCLC quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8+, CD4+, CD20+ B cells; PD‐1, LAG3, and TIM‐3T cells with outcomes.